News – Page 902 – Endpoints News

Boston jury finds biotech CEO guilty of fleecing investors, obstruction of justice

6 years ago

Mirati team demonstrates that their KRAS G12C drug is active in NSCLC — but how do they stack up next to Amgen?

6 years ago

AstraZeneca’s triplet with Imfinzi, treme and chemo works on a key endpoint for frontline lung cancer

6 years ago

Here’s a new way to raise money for your biotech. This trailblazer came out $61M ahead with a place on the NYSE

6 years ago

FDA backs Mike Grey's bet on a comeback drug play with breakthrough status for maralixibat

6 years ago

Allergan ties up Namenda loose ends with $750M settlement

6 years ago

FDA accepts Heron's painkiller re-submission; splits Blueprint Medicines' NDA for avapritinib

6 years ago

A deal-hungry Vertex ushers in three more gene editing programs as it closes out harbinger CRISPR deal

6 years ago

David Hung is back, launching a new oncology startup with $275M and big ambitions to make news in cancer drug ...

6 years ago

Google’s venture arm recruits a Harvard/Tesaro vet to help plant the seeds for a second oncology R&D revolution

6 years ago

Mixed early data on Agios' AG-270 suggest combo therapy could be way forward

6 years ago

A GSK-led consortium looks to break ground with a new class of antibiotic, pushing into a pivotal

6 years ago

Ascentage soars during its first day on the Hong Kong exchange, following $53M debut

6 years ago

The human element: A biotech upstart hopes to carve a path around faulty animal models

6 years ago

Diving deep into AMD, Yale researchers pinpoint cell types drug developers should pay special attention to

6 years ago

China's Fountain Medical scores $62M as demand for CRO services surges

6 years ago

Christopher Haqq joins Elicio to hunt father's RAS cancer; Kronos expands top team with Gilead, Baylor vets

6 years ago

Provention Bio's diabetes drug gains PRIME status; Avrobio earns orphan status

6 years ago

AbbVie doubles down on cystic fibrosis R&D, adding a new drug to the pipeline as Vertex seals its domination of the ...

6 years ago

FDA revises guidance on postmarketing studies to reflect ARIA system, SUPPORT act

6 years ago

A tale of two IPOs (plus one): Cabaletta prices well below range for $75M while Phathom bags $182M

6 years ago

Novartis sends second wagon after KRAS gold rush

6 years ago

Gilead execs flag trial failures for Sjögren’s and lupus drugs — while swapping out a favorite HIV program of ...

6 years ago

FTC staff signs off on Roche $4.3B deal for Spark — report

6 years ago

First page Previous page 899 900 901902903 904 905 Next page Last page